Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
Pulse Biosciences, Inc., a Delaware corporation, filed this Current Report on Form 8-K on February 19, 2026. The filing serves to announce financial and operational results for the fiscal quarter and full year ended December 31, 2025. The company's principal executive offices are located in Miami, Florida.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this filing. The document indicates that such information is available in the attached press release (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It explicitly states that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for Q4 and FY 2025.
- Verify the company's liquidity position and cash runway as detailed in the attached press release.
- Check for any updated forward-looking guidance or operational milestones mentioned in the business update.
- Confirm the status of the company's emerging growth company designation, which is not checked in this filing.